CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapyAmelie Franken, Diether Lambrechts, Jeroen Van Dessel et al.|Immunity|2024Cited by 108
Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.Michel Bila, Paul M. Clément, Amelie Franken et al.|Journal of Clinical Oncology|2023Cited by 2